These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17519959)

  • 21. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
    Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
    Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.
    Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M
    Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K; Kodama A; Ohyashiki JH
    Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
    Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
    Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
    Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.
    Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Saumell S; Salar A; Abella E; Gimeno E; Serrano S; Florensa L; Sánchez B; Pedro C; Besses C
    Br J Haematol; 2009 Sep; 146(5):504-9. PubMed ID: 19604233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
    Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
    Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Vascular complications of essential thrombocythemia].
    Bellucci S
    Bull Acad Natl Med; 2007 Mar; 191(3):519-30; discussion 530-3. PubMed ID: 18072651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
    Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
    Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Essential thrombocythemia: scientific advances and current practice.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
    Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
    Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.
    Lee HS; Park LC; Lee EM; Lee SJ; Shin SH; Im H; Do KM; Kim EJ; Ye BJ; Song MK; Kim SH; Lee SM; Lee WS; Kim YS
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):70-5. PubMed ID: 22088920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.